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        This study was performed to determine the effects of fibroblast growth factor-2 (FGF-2) 
on monolayer expansion of equine tendon- and bone marrow-derived cells prior to culture 
with autogenous acellular tendon matrix and insulin-like growth factor-I (IGF-I). 
Progenitor cells were isolated from six young adult horses, expanded in monolayers with 
FGF-2, and cultured with autogenous acellular pulverized tendon and IGF-I for seven days. 
Initial cell isolation and subsequent monolayer proliferation were assessed.  In the cell: 
pulverized tendon cultures, cell viability, expression of collagen types I and II, and cartilage 
oligomeric matrix protein (COMP) mRNAs, collagen and glycosaminoglycans (GAG) 
syntheses were assessed. Tendon-derived cells proliferated significantly more rapidly in the 
initial monolayer expansion cultures in comparison to bone marrow-derived cells. Further, 
monolayer expansion with FGF-2 significantly increased the cell numbers of tendon-derived 
cells. Expression of collagen type I, collagen type III and COMP mRNAs was higher in 
tendon-derived cell groups than bone marrow-derived cell groups. However, IGF-I 
supplementation significantly increased collagen type I and type III mRNA expression in 
only the bone marrow-derived cell groups. IGF-I supplementation significantly increased 
collagen synthesis of bone marrow-derived cells. Monolayer expansion with FGF-2 followed 
by IGF-I supplementation significantly increased proteoglycan synthesis in tendon-derived 
cells. In summary, tendon-derived cell cultures generated more cells and showed increased 
matrix synthesis following monolayer expansion with FGF-2 when compared to bone 
marrow-derived cells. In vivo experiments using FGF-2 expanded tendon-derived cells are 
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         Flexor tendon injuries are among the most common musculoskeletal injuries that 
contribute to the loss of athletic use of horses (Dowling et al. 2000, Dyson 2004, Ely et al. 
2009, Genovese et al. 1996). In addition, the risk of tendon injury increases with age. The 
healing response is prolonged following tendon injury and the resultant repair tissue is 
usually of inferior mechanical strength. Consequently, the prognosis for return to previous 
levels of performance is poor (Dowling et al. 2000, Lam et al. 2007). A variety of surgical 
and conservative treatments have been developed, however none have succeeded in returning 
the healed tendon to its original strength (Bramlage 1991, Alves et al. 2001, Crowe et al. 
2004, Hawkins, Ross 1995, Gibson, Burbidge & Pfeiffer 1997). Re-injury, despite prolonged 
and costly rehabilitation, is common.     
         The inability of equine tendon to regenerate after injury, or to heal with mechanical 
properties comparable to the original tissue is likely due to the low vascularity and cellularity 
of the tissue, the low number of progenitor cells within the tissue, and healing under weight-
bearing conditions (Birch 2007a, Birch et al. 2008, Hosaka et al. 2005, O'Brien 1997).  
Additionally, it is thought that tendinitis is due to a long-term degenerative process rather 
than one episode of trauma (Birch, Bailey & Goodship 1998, Birch, Wilson & Goodship 
2008). Strategies to improve tendon healing have aimed at enhancing the metabolic response 
of the injured tenocytes, modulating the organization of the extracellular matrix produced, or 
administering progenitor cells to enhance repair tissue (Krampera et al. 2006, Lacitignola et 
al. 2008, Richardson et al. 2007a). The use of mesenchymal stem cells (MSCs) for tissue 
repair, regeneration and engineering has been an extremely dynamic area of research over the 
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past decade. The majority of these studies have focused on the use of MSCs derived from 
bone marrow population. However more recent studies indicate that alternative sources of 
progenitor cells (fat, synovium, cartilage, and muscle) might also be beneficial for specific 
therapeutic applications (Ju et al. 2008, Nixon et al. 2008). The most prominent avenues of 
investigation have been directed at repair of bone, cartilage, myocardium and CNS tissues 
(Caplan 2007a, Caplan 2005a).  
         Bone marrow-derived MSCs have been used for tendon repair in horses, rabbits, and 
rats (Lacitignola et al. 2008, Pacini et al. 2007, Smith 2008a, Smith et al. 2003). To date, the 
studies performed in horses using bone marrow derived MSCs for tendon repair have been 
subjective with no clear, objective evidence of efficacy. Despite the lack of objective 
evidence, over 1,000 horses have been treated with intratendinous injections of direct bone 
marrow aspirates or adipose-derived progenitor cells over the last four years (Nixon et al. 
2008, Smith 2008a). However, none of these studies used a homogeneous population of stem 
cells to repair tendon and one study documented bone formation within the tendon repair 
tissue (Dressler, Butler & Boivin 2005). A recent equine study using adipose-derived source 
of progenitor cells for treatment of a collagenase-induced model of tendinitis showed only 
histological improvement of repair over the untreated control, with no biomechanical data to 
substantiate improved outcomes (Nixon et al. 2008). Currently, stem cell therapy in 
veterinary medicine has generated a vast amount of revenue from clientele with minimal 
scientific follow-up on clinical cases.   
         Alternate sources of progenitor cells have been described for tendon repair in other 
species (Ju et al. 2008, Cao et al. 2002, Liu et al. 2006). However, there are only a few 
studies utilizing an equine model of tendinitis treated with alternate sources of progenitor 
 3 
cells (Nixon et al. 2008). Recent lines of evidence suggests the presence of multipotent, 
clonogenic population of progenitor/stem cells in tendons, within an extra cellular matrix 
(ECM)-rich niche (Bi et al. 2007, Salingcarnboriboon et al. 2003, Rui et al. 2010)). One 
study showed tendon and muscle-derived cells proliferated more rapidly in monolayer 
cultures and had better viability and matrix production, compared to bone marrow-derived 
cells (Stewart et al. 2009a). A differential adherence preplating technique has been used in 
this study to isolate autogenous equine tendon-derived progenitor cells from the lateral digital 
extensor tendon. This method has been adapted from a technique described to isolate 
myogenic cells, a progenitor cell population in skeletal muscles (Gharaibeh et al. 2008, 
Jankowski et al. 2001). 
         Growth factors function as anabolic signaling peptides, resulting in cell proliferation 
and differentiation, up-regulation of cell metabolism, and synthesis of extracellular matrix. 
Fibroblast growth factor-2 (FGF-2), also known as basic fibroblast growth factor is a potent 
mitogen that binds to heparan-sulfate proteoglycans in the tendon extracellular matrix and is 
released with matrix degeneration (Dahlgren, Mohammed & Nixon 2005, Duffy et al. 1995, 
Chan et al. 2000). Mesenchymal stem cell cultures supplemented with FGF-2 proliferate 
more rapidly and exhibit an increased capacity for self-renewal and differentiation (Solchaga 
et al. 2010, Stewart et al. 2007). The authors have evaluated the effects of FGF-2 on equine 
bone marrow-derived MSCs at concentrations of 1, 10, and 100 ng/mL (Stewart et al. 2007) 
Optimal effects were reported at 100 mg/mL (the concentration used in this study). In 
addition, several in vitro and in vivo murine and lupine studies of tendon healing have shown 
enhanced angiogenesis, tendon fibroblast proliferation, and collagen type III expression in 
response to FGF-2 administration (Chan et al. 2000, Chan et al. 1997, Wang et al. 2005).   
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         The role of insulin-like growth factor-I (IGF-I) in equine tendon healing has generated 
a considerable body of research in the last few years. In vitro, IGF-I stimulates mitogenesis, 
matrix gene expression, and collagen synthesis by tenocytes(Abrahamsson, Lundborg & 
Lohmander 1991)(Costa et al. 2006). Further, exogenous injections and gene therapy 
delivery of IGF-I have resulted in histological improvement in tendon healing following 
collagenase-induced tendinitis (Dahlgren et al. 2002, Schnabel et al. 2009). The dose-
dependent effects of IGF-I on in vitro tenocyte matrix synthesis were evaluated by 
Abrahamsson et al (Abrahamsson, Lundborg & Lohmander 1991). Collagen synthesis was 
significantly increased at 100 and 250 ug of IGF-I/mL doses. A concentration of 100ug of 
IGF-I/mL was selected for use in the current study, on the basis of published results and the 
outcomes of previous stem cell-focused studies completed in the author’s laboratory. The 
beneficial effects of IGF-I are increased mitogenesis, tendon gene expression, and collagen 
synthesis (Abrahamsson, Lundborg & Lohmander 1991, Olesen et al. 2006).  
         For clinically viable applications of cell-based therapies, the in vitro expansion of 
putative progenitor cell populations needs to be optimized to reduce the time required for 
generation of adequate cell numbers. Additionally, the biosynthetic activities of re-implanted 
cells need to be augmented to promote healing through effective tissue repair. Therefore, this 
study addressed two major objectives. Firstly, the mitogenic effects of FGF-2 on tendon- and 
bone marrow-derived cell populations were assessed during in vitro monolayer expansion. 
Secondly, the synthetic and phenotypic responses of monolayer-expanded cells to exogenous 
IGF-I were assessed in an in vitro “powdered matrix” model. Pulverized tendon derived from 
an autogenous source has been used as substrate material to provide a three-dimensional 
plane for cell adhesion/proliferation and matrix synthesis.  
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         The goals of this Master’s project are two-fold: 
(1) To determine whether FGF-2 supplementation during monolayer expansion can 
enhance the proliferative capacity and matrix synthesis of both tendon- and bone 
marrow-derived cells. 
(2) To evaluate whether IGF-I supplementation alone or following FGF-2 monolayer 
expansion would have a beneficial effect on cell proliferation, tendon gene 
expression, and  matrix synthesis of tendon- and bone marrow-derived cells cultured 
with tendon matrix. 
         The overall objective of this study was to determine whether sequential administration 
of FGF-2, during monolayer expansion, and IGF-I in culture with pulverized tendon, would 
improve cell expansion and subsequent matrix synthesis. My hypothesis was that tendon-
derived cells expanded with FGF-2 and cultured with pulverized tendon and IGF-I 
supplementation will have increased cell viability/ proliferation, matrix gene expression, and 














         Flexor tendon injuries are amongst the most common musculoskeletal injuries that 
contribute to the loss of athletic use of horses (Dowling et al. 2000, Thorpe, Clegg & Birch 
2010). Further, the healing process following tendon injury is prolonged and the resultant 
repair tissue is of inferior mechanical strength. Consequently, the prognosis for return to 
previous level of performance is poor (Patterson-Kane, Firth 2009). Recent management and 
treatment strategies do not return the healed tendon to its original strength. Re-injury, despite 
prolonged and costly rehabilitation, is common. Cell-based approaches with or without 
growth factor enhancement have been a recent focus in tendon research with an ultimate goal 
of better histological organization and biomechanical strength (Lacitignola et al. 2008, 
Schnabel et al. 2009, Richardson et al. 2007b, Smith 2008b).  
 
Structure and Function of Tendons 
         Tendons are dense collagenous tissues that connect muscles to bones. Based on their 
function, equine tendons can be classified as ‘weight-bearing’ tendons that store and release 
elastic strain energy, increasing the efficiency of locomotion (e.g., digital flexor tendons) 
(Figure 1) and ‘positional’ tendons that transmit muscle generated forces to bones resulting 
in movement around joints (e.g., digital extensor tendons) (Birch 2007a). Tendons are 
complex organs, composed of a hierarchical arrangement of smaller subunits (Figure 2). 
Morphologically, in cross-section tendons are divided into a number of fascicles, which are 
in turn composed of collagen fiber bundles and then fibrils (O'Brien 1997, Benjamin, Kaiser 
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& Milz 2008). The fascicles are held together by a loose areolar connective tissue, the 
endotenon, which becomes confluent with the outer epitenon. The epitenon is surrounded by 
the paratenon, a fine connective tissue sheath which functions as an elastic sheath to permit 
free movement of the tendon against the surrounding structures. Tendons consist primarily of 
collagen fibers oriented in the direction of force application.  The collagen molecules are 
stabilized by intermolecular chemical crosslinks resulting in high tensile strength (Avery, 
Bailey 2005).  
Molecular composition 
         Tendons are composed predominantly of water (70%) and cells, extracellular matrix, 
enzymes (30%) (Fu et al. 2002). The matrix is composed mainly of collagen and some elastin 
embedded in a proteoglycan-water matrix. Collagen accounts for 65-80% and elastin about 
1-2% of the dry mass of the tendon (Hosaka et al. 2010). These components are produced by 
tenoblasts and tenocytes, which are elongated fibroblasts interspersed between the collagen 
fibers (Kannus 2000). 
         Collagen type I is predominant and accounts for about 90% of total tendon collagen, 
with a small portion comprised of collagen type III, about 4-5%, thought to form smaller and 
weaker fibrils (Patterson-Kane, Firth 2009). In the fibro-cartilaginous regions, collagen types 
II, IX, X and XI, may also be found (O'Brien 1997). Collagen type IV is found in the 
basement membrane with a trace of type V collagen (Dowling et al. 2000, O'Brien 1997). 
The structural unit of collagen is tropocollagen or a microfibril, consisting of three 
polypeptide chains wound together to form an alpha triple helix. These alpha chains are 
composed primarily of proline and glycine, present as every third residue. Several of these 
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microfibrils unite to form a fibril, and many fibrils are embedded in the extracellular matrix 
as collagen fibers.   
         Proteoglycans and glycoproteins combine to form a ground substance, accounting for 
1-2% of the dry mass of the tendon (O'Brien 1997, Kannus 2000). The ground substance 
surrounds the collagen fibers and plays an important role in collagen fibrillogenesis and 
cellular interactions (Patterson-Kane, Firth 2009). Proteoglycans are composed of a core 
protein associated with four main glycosaminoglycans; dermatan sulfate, chondroitin sulfate, 
keratan sulfate and heparan sulfate (O'Brien 1997). Proteoglycans in tendons can be 
classified as, small leucine-rich proteoglycans such as decorin, biglycan and lumican, and 
large aggregating proteoglycans such as aggrecan and versican. The most abundant tendon 
proteoglycan is decorin, followed by biglycan, and others include, fibromodulin, lumican, 
aggrecan and versican (Yoon, Halper 2005). Decorin is considered as a key regulator of 
matrix assembly as it limits collagen fibril formation and directs tendon remodelling in 
relation to tensile forces (Danielson et al. 1997). 
         Cartilage oligomeric matrix protein (COMP) is an abundant non-collagenous 
glycoprotein in tendons that increase with growth and decline after maturation (DiCesare et 
al. 1994). It is a calcium binding pentamer, with each subunit shown to bind collagen type I, 
II and IX. Higher levels of COMP are reported in superficial digital flexor tendons (SDFT) as 
compared to deep digital flexor tendons (DDFT) (Sodersten et al. 2005). COMP 
concentrations are correlated with weight bearing and mechanical properties of the 
superficial digital flexor tendon (Dowling, Dart 2005). Further, higher COMP levels are 
found in association with small diameter collagen fibrils in the tensional area of the flexor 
tendons. It has been proposed that COMP functions to provide structural integrity to the 
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extracellular matrix by binding to multiple collagen fibrils in collagen fibrillogenesis 
(Sodersten et al. 2005, Dowling, Dart 2005).  
     
    The cellular compartment of tendons constitutes a very small portion of the total bulk of 
the tissue. Further, the cell-to-matrix ratio gradually decreases over age. Tenocytes are 
fibroblastic cells that are responsible for synthesis and turnover of the tendinous extracellular 
matrix. Tenocytes are arranged in parallel rows along the longitudinal axis of tendons, with 
gap junctions linking flattened cytoplasmic processes that extend through the extracellular 
matrix between cells (Stanley et al. 2007). Type 1, 2 and 3 tenocytes have been defined in 
equine tendons (Stanley et al. 2008). Type 1 tenocytes referred to as ‘tenocytes’ have long, 
thin spindle-shaped nuclei whereas type 2 tenocytes referred to as ‘tenoblasts’ have plump, 
cigar-shaped nuclei (Patterson-Kane, Firth 2009). Type 3 tenocytes are chondrocyte-like with 
round nuclei and are located at sites exposed to compressive forces, especially where tendons 
wrap around joints (Stanley et al. 2008). Type 2 cells are metabolically more active and have 
a higher biosynthetic capacity than type I cells and are present in a higher proportion in fetal 
and neonatal tendon. With increasing age, the proportion of type 1 tenocytes increases, along 
with a reduction in total cellularity and cellular activity (Patterson-Kane, Firth 2009, 
Dowling, Dart 2005, Stanley et al. 2008).     
Histological structure 
         Histologically, tendons have a highly organized structure (Figure 3). Linear fibers of 
collagen are aligned along the longitudinal axis in each fascicle. Tenocytes are located both 
intrafascicularly and interfascicularly, arranged in rows along the direction of the collagen 
fibers (Thorpe, Clegg & Birch 2010). Vascular channels are present in the endotenon. A 
characteristic crimp pattern of collagen fibers is a typical ultra-structural feature of tendons 
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(Figure 4). The crimps function as a buffer to allow longitudinal elongation in response to 
physiological tensile loads (O'Brien 1997). In addition, on tensile loading the central fibers 
straighten first and therefore receive a higher load. As age increases, a generalized reduction 
in crimp angle occurs, with a greater degree of reduction in central fibers (Patterson-Kane et 
al. 1997). 
Physiologic matrix turnover 
         Native tenocytes are involved in constant matrix remodelling under normal 
circumstances by synthesizing collagen, proteoglycans, and enzymes responsible for 
degradation, such as matrix metalloproteinases (MMPs). Tendons have low oxygen 
consumption values in comparison to other tissues. The low metabolic rate with well-
developed anaerobic energy production is adapted for load-bearing for prolonged periods of 
time (Kannus 2000). However, the rate of recovery after activity is consequently slow.  
         Synthesis of collagen occurs intracellularly in tenocytes, with the formation of mRNA 
for each alpha chain which are then assembled on the polyribosomes bound to rough 
endoplasmic reticulum, and stored as preprocollagen (Zhang et al. 2005). Soluble 
procollagen is formed from the preprocollagen, followed by hydroxylation of proline and 
lysine. The procollagen is secreted extracellularly to form insoluble tropocollagen, which 
aggregates to form collagen fibrils (Zhang et al. 2005). 
    
      Synthesis of proteoglycans also occurs intracellularly, in the rough endoplasmic 
reticulum of tenocytes, where the core protein is assembled and glycosylation is initiated. 
The process is completed in the Golgi complex, where sulfation takes place (O'Brien 1997).  
The continual process of matrix remodelling is primarily mediated by proteases acting in the 
extracellular environment. These include MMPs and aggrecanases from the “a disintegrin 
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and metalloproteinase with thrombospondin motifs” (ADAMTS) family. The activity of 
MMPs is highly regulated by tissue inhibitors of metalloproteinase (TIMPs) (Riley, 
Medscape 2008). Gelatinases, MMP-2 and -9, and collagenases, MMP-1 and -13, are thought 
to be involved in tendon metabolism, through their broad proteolytic capacity. Their activity 
is reversibly inhibited by TIMPs-1 and -2. A balance between the activities of MMPs and 
TIMPs regulates tendon remodeling (Karousou et al. 2008). ADAMTS-2, -3, and -14 are pro-
collagen peptidases, and function as regulators of collagen fibril assembly. ADAMTS-1 and -
4 are capable of cleaving matrix proteoglycan versican and glycoprotein COMP (Hosaka et 
al. 2002). 
       Energy-storing flexor tendons experience higher strains during physiological activity 
than positional extensor tendons (Birch, Wilson & Goodship 2008). Also, functionally 
distinct tendons differ in matrix composition, with a higher glycosaminoglycan, COMP, 
water content and cellularity in SDFTs when compared to common digital extensor tendon 
(CDET) (Birch et al. 2008). Historically, tendon was assumed to be a relatively inert tissue, 
however, a recent study reported active tendon matrix turnover (Birch 2007b). The same 
study reported a difference in the rate of matrix turnover between functionally distinct 
tendons in the absence of disease process, with a lower level of collagen gene expression and 
MMP activity in SDFT when compared to DDFT.   
 
Superficial Digital Flexor Tendinitis in Horses 
         Musculoskeletal injuries involving tendons and ligaments are a major cause of career-
ending lameness in performance horses. A recent study in National Hunt horses showed that 
46% of the injuries involved tendons and ligaments (Ely et al. 2009). Some tendons are more 
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prone to injuries than the others, with the majority occurring in the forelimbs (97-99%) as 
they bear 60% of the total body weight during rest and more during galloping. Superficial 
digital flexor tendons are commonly affected due to its small cross-sectional area, small 
margin of safety and high tensile loads experienced at maximal exertion. The same study 
reported superficial digital flexor tendon injuries in about 89% of all tendon and ligament 
injuries and the remainder involved the suspensory ligament. Another study described the 
prevalence of SDF tendinitis in Thoroughbred racehorses in Hong Kong to range from 25-
53% with 97% of these occurring in the forelimbs (Dyson 2004). Superficial digital flexor 
tendinitis was described as the most common cause of retirement in this population of equine 
athletes. There is a high risk of re-injury following prolonged rehabilitation. Studies report 
successful return to racing in 20-60% of the affected horses but up to 80% of these horses 
sustained re-injury (Dowling et al. 2000, Genovese et al. 1996). Results of another study 
revealed 96% of the horses returned to previous function, but the re-injury rate was 42.5- 
44%, with a higher rate in horses used for flat racing (Dyson 2004).    
Pathophysiology     
        The cross-sectional area of the SDFT is smallest at the mid-metacarpal region. 
Consequently, this site is highly susceptible to injury, as the central collagen fibers take more 
load than the peripheral fibers (Patterson-Kane, Firth 2009). One study, evaluated the 
incidence of tendinitis in the proximal aspect of the SDFT in older performance horses 
(Chesen et al. 2009). Tendinitis or more accurately termed ‘tendinopathy’ is a result of 
chronic overuse rather than a single event to failure. Localized microdamage to collagen 
fibrils can occur when the SDFT is exposed to high strains up to 19%. This isolated fibrillar 
damage causes an alteration in cell-matrix interactions leading to increased matrix 
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breakdown in relation to cellular repair mechanisms (Patterson-Kane, Firth 2009). This 
‘tendinopathy’ cycle results in further weakening due to repeated and cumulative 
microtrauma, where insufficient time is provided to effect repair between traumatic episodes.  
         Limb motion generates considerable heat in the peripheral tissues. An increase in core 
temperature of up to 5.40C has reported in the mid-cannon SDFT as a consequence of kinetic 
energy being released as heat. Some evidence suggests that this hyperthermia can result in 
damage to extracellular matrix and cell death (Wilson, Goodship 1994). However, a 
contradictory outcome was reported by Hosaka et al, with 70-90% cell survival following 
heating of tenocyte suspensions for up to 10 minutes (Hosaka et al. 2005, Birch, Wilson & 
Goodship 1997). Another study reported apoptosis of tenocytes in inflamed SDFT via a 
caspase-3-dependent pathway as a cause of cell death (Hosaka et al. 2006).    
         An inflammatory cascade associated with cytokine release takes place following injury. 
Increased expression of IL-1α, IL-1β, TNF-α, and IFNγ has been reported in inflamed SDFTs 
(Hosaka et al. 2002). Both the expression and activity of MMPs are stimulated by pro-
inflammatory cytokines. There is increased expression of MMPs-2 and -9, along with a 
down-regulation of TIMP-1 in chronic tendinopathy (Karousou et al. 2008, Riley 2005). A 
local imbalance in MMPs and TIMP activities can cause progressive degeneration and 
weakening of the extracellular matrix of tendons. A study conducted in human ruptured 
supraspinatus tendons showed increased MMP-1 levels, causing degradation of the collagen 
fibril network (Riley et al. 2002). Expression of ADAMTS-1, -4, and -5 has also been shown 
in tendon (Riley et al. 2002). However, their levels of expression and activity are still unclear 
in tendinopathies. As a consequence to the inflammatory process and proteolytic activities, 
intra- and inter-molecular cross-links within collagen fibrils break down, leading to fibril 
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elongation at the microscopic level followed by macroscopic changes (Patterson-Kane, Firth 
2009).        
         Degeneration of the SDFT is characterized by discoloration of the central core region 
accompanied by swelling. Fibril diameter also changes, with a predominance of small-
diameter collagen fibrils which ultimately decreases the tensile strength of injured tendons, 
and increases the susceptibility to re-injury. Microscopically, increased cellularity with 
inflammatory cell infiltrates, cell rounding, and disruption of collagen fiber organization is 
observed (Riley, Medscape 2008). Collagen type III mRNA expression increases following 
injury with a sequential increase in collagen type III content (Dahlgren, Brower-Toland & 
Nixon 2005, Samiric et al. 2009). Some studies report a decrease in mRNA expression of 
collagen type I in diseased tendon, with no difference in collagen type I content (Samiric et 
al. 2009). Parallel studies conducted in injured human Achilles tendons show increased 
collagen type I mRNA levels with a sequential increase in collagen turnover (de Mos et al. 
2007b). However, the percentage of denatured collagen was higher with a poor quality 
collagenous matrix. In contrast, a recent study showed no significant increase in expression 
of collagen type I mRNA in acute tendinopathy (Taylor et al. 2009). In addition, no 
significant change in total collagen content was seen in equine SDF tendinopathy (Birch, 
Bailey & Goodship 1998). An increase in sulfated glycosaminoglycans (sGAGs) and water 
content occurs in tendinopathies which gives rise to tissue swelling (Samiric et al. 2009). A 
significant increase in large aggregating (proteoglycans, versican, and aggrecan) and small 
proteoglycans (biglycan and fibromodulin) has been reported, with no changes in levels of 
decorin (Samiric et al. 2009).  
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Process of Tendon Healing  
         There are three phases in tendon healing; the reactive inflammation phase, the acute 
reparative or proliferative phase, and the chronic remodelling or maturation phase. 
Reactive inflammation 
         This phase lasts for about a week and is characterized by a marked increase in cross-
sectional area at and around the site of injury with local hemorrhage and edematous swelling. 
This is followed by inflammatory cell infiltration, initially by neutrophils, with predominant 
macrophage accumulation after 24 hours to phagocytize debris and necrotic cells. 
Consequently, this causes a release in proteolytic enzymes and results in further mechanical 
disruption. 
         Changes in growth factor expression occur immediately following injury. Studies show 
increased expression of transforming growth factor- β1 (TGF-β1) in early stages of tendon 
healing. The large round cells within the endotenon have a higher expression of TGF- β1 
when compared to those within the lesional tissue (Dahlgren, Mohammed & Nixon 2005, 
Berglund et al. 2006). In addition, expression of connective tissue growth factor (CTGF) 
significantly decreases in the tendon sheath following injury with no change in the tendon 
tissue (Berglund et al. 2006). The same study reported an increased expression of basic 
fibroblastic growth factor (bFGF) in tendon tissue at the same time point. Studies also 
indicate minimal increase in expression of insulin-like growth factor-I (IGF-I) in acute stages 
of tendon healing (Dahlgren, Mohammed & Nixon 2005), (Berglund et al. 2006). During the 
reactive inflammatory phase there is a marked increase in mRNA expression of collagen type 
III and type I in a collagenase-induced tendinitis (Dahlgren, Mohammed & Nixon 2005). The 
percentage composition of collagen type III begins to increase in this early phase. 
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Proliferation 
         This phase begins within a few days of injury and peaks for about 2 to 3 weeks. 
Neovascularization is a dominant feature of this phase, slowly replacing the inflammatory 
cell infiltrates. Proliferation of fibroblasts takes place from surrounding endotenon and 
epitenon. Tenocytes in the peri-lesional tissue may also undergo cell division, leading to 
increased cellularity at the site of injury. Fibroblastic cells that are proliferating have a 
rounded appearance with plump nuclei, with a tenoblast-like appearance (Dahlgren, 
Mohammed & Nixon 2005).   
         Growth factors responsible for angiogenesis and mitogenesis regulate tissue activities 
during this phase. Vascular endothelial growth factor (VEGF), a prototypic angiogenic 
growth factor is up-regulated in early tendon healing (Dahlgren, Mohammed & Nixon 2005, 
Patterson-Kane, Firth 2009, Fenwick, Hazleman & Riley 2002), (Patterson-Kane, Firth 2009, 
Dahlgren, Brower-Toland & Nixon 2005). Expression of bFGF increases during this phase. 
bFGF also has angiogenic effects in healing tendons (Duffy et al. 1995). IGF-I mRNA 
expression levels are reported to peak around 4 weeks following injury in a collagenase-
induced model of tendinitis (Dahlgren, Mohammed & Nixon 2005). IGF-binding proteins 
(IGFBPs) regulate the activity of IGF-I by restricting its bioavailability to IGF-I receptors. In 
addition, IGFBPs are also thought to protect IGF-I from proteases. Increased expression of 
IGFBP-2, -3 and -4 occurs between 2-4 weeks following tendon injury and decreased 
expression of IGFBP-5 and -6 is present throughout healing period for up to 24 weeks 
(Dahlgren, Mohammed & Nixon 2006). The mitogenic effect of IGF-I plays an important 
role in stimulating cell proliferation in this phase of healing (Dahlgren, Mohammed & Nixon 
2005).   
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         In a collagenase-induced tendonitis study, mRNA expression for collagen type I was 
six-fold higher than collagen type III. Collagen type III mRNA expression was localized to 
cells within the endotenon in early stages of healing followed by intralesional tenocytes 
during later stages of healing (Riley et al. 2002). Synthesis of collagen type III peaked 3-6 
weeks post-injury, comprising up to 35% of total collagen by 1-2 weeks and remained high 
for up to 4 weeks post-injury. Collagen type I fell to approximately 66% by 1 week following 
injury. A larger proportion of small fibrils began to form in the healing response with inferior 
mechanical properties. One study showed increased mRNA expression of versican around 6 
days post-injury and of aggrecan around 24 days post-injury in rabbit flexor tendons 
(Berglund et al. 2006). A decreased expression of decorin, and a relative increase in 
expression of biglycan were also evident in injured tendons when compared to normal 
tendons. 
Remodelling 
         The remodelling or maturation phase is characterized by formation of fibrous tissue. 
During this stage, the healing tissue undergoes changes in size and shape. This phase is 
divided into consolidation and maturation processes (Sharma, Maffulli 2006). The 
consolidation stage begins at about 6 weeks and continues for up to 10 weeks post injury. 
The repair tissue changes from cellular to fibrous. However, increased vascularity and 
cellularity persists for up to 3 months post-injury (Patterson-Kane, Firth 2009, Fenwick, 
Hazleman & Riley 2002). Tenocyte nuclei gradually become more spindle-like with an 
increased synthetic activity early on which gradually decreases.  
         Persistent increases in TGF- β1 and IGF-I mRNA levels remained up to 6 months post-
injury. These increases were restricted to mature fibroblasts within the healing tendons 
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(Dahlgren, Mohammed & Nixon 2005). In addition, mRNA expression of collagen type I and 
type III was increased up to 6 months post-injury. A higher proportion of collagen type I was 
synthesized during this stage. However, collagenous tissue may still be randomly oriented 
with thickened areas of endotenon due to increased numbers of blood vessels (Patterson-
Kane, Firth 2009). 
         The maturation stage begins after approximately 10 weeks, marked by a gradual change 
from fibrous tissue to scar-like tendon tissue. This transition continues for up to a year 
(Sharma, Maffulli 2006). The newly formed collagen fibrils begin to orient longitudinally 
along tensile forces. The larger diameter collagen fibrils are not replaced following healing. 
The tendon cross-sectional area often remains increased, along with increased tissue mass. 
Healed tendons have decreased elastic properties and do not regain the original mechanical 
strength. Peritendinous fibrosis often occurs following healing with adhesions to adjacent 
structures that can significantly interfere with normal function. Together, the abnormal 
composition and arrangement of fibers, poor biomechanical properties, and prolonged period 
of healing are responsible for high occurrence of re-injury.  
 
Treatment of Tendinitis 
          Many treatment strategies have been advocated for equine tendonitis, depending on 
phase of healing. Also, therapeutic approaches differ depending on the duration of time since 
the original insult.  
Acute tendon injuries  
         Acute tendon injuries constitute a medical emergency that require rapid reduction of 
inflammation. Failure to reduce tendon inflammation can lead to further damage. Physical 
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therapies, which include ice application, cryotherapy, and compression bandaging, and 
immediate controlled mobilization are important for reducing inflammation and limiting the 
action of proteolytic enzymes on tendon extracellular matrix (Bramlage 1991). Cryotherapy 
exerts a beneficial effect through local vasoconstriction, decreased enzymatic activity, and 
reduced formation of inflammatory mediators. Cryotherapy for 20 minutes at frequent 
intervals is advised. One study reported reduction in core temperature of equine SDFT to 
21.80C with no effects on the viability of tenocytes following cryotherapy for 1 hour (Petrov 
et al. 2003). Pressure applied by compression bandaging with coaptation also reduces 
inflammation and edema formation. Coaptation by application of a palmar splint or heel 
support may be carried out to provide further support to the tendon. Administration of 
systemic non-steroidal anti-inflammatory drugs (NSAIDs) such as phenylbutazone and 
flunixin meglumine has been advocated in the acute stages to reduce inflammation and to 
provide analgesia (Dowling et al. 2000, Bramlage 1991).  
Chronic tendinopathies  
         Both, medical and surgical treatment options have been described for chronic 
tendinopathies with little objective evidence for continuing beneficial effects (Dowling et al. 
2000). A brief review of various therapeutic options is provided below. 
 
Medical Management of Tendinitis 
Controlled exercise programs  
         Earlier studies have extensively evaluated controlled exercise programs as a 
conservative approach for rehabilitation of SDFT injuries with the goal of maintaining 
gliding function, and promoting optimal collagen healing. It involves gradual increase in 
 20 
exercise regimen over a protracted period of time, up to about a year, with careful monitoring 
with diagnostic ultrasound at 3 month intervals (Gills 1997). One study showed 71% of 
injured horses returned to performance following controlled exercise when compared to 25% 
of injured horses with pasture rest (Gills 1997). Other studies reported similar results with 
59-75% of injured horses returned to performance following controlled exercise (Sawdon, 
Yovich & Booth 1996, Marr et al. 1993). However, these studies failed to document the 
severity of the initial lesions, which may have an important influence on the outcome. 
Extracorporeal shock wave therapy  
         Extracorporeal shock waves are pressure waves generated outside the body. These 
pressure waves cause high local stresses and analgesic effects on sensory nerves, possibly 
through demyelination of nerves. One study reported a return to performance in 50% of the 
horses with injured proximal suspensory ligaments following shock wave therapy 
administered 3 times at 2-week intervals (Crowe et al. 2004). Another study reported 
increased neovascularization with no ultrasonographic improvement in collagenase-induced 
SDF tendinitis in horses at 12 weeks post-injury treated with three treatments of shock wave 
therapy at 3-week intervals (Kersh et al. 2006). A recent study showed increased gene 
expression of collagen type I and MMP-14 with disorganization of matrix structure in normal 
tendons 6 weeks post-exposure to shock waves, suggesting a potential harmful effect on 
surrounding normal tissue (Bosch et al. 2009).  
Therapeutic ultrasound  
         A few studies have reported the effect of therapeutic ultrasound for tendinopathies in 
human athletes. Beneficial effects have been shown to be due to increased cell migration and 
gene expression, along with histologic improvement in entheseous insertions of tendon to 
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bone (Tsai et al. 2008, Moraes et al. 2009). However, there are no scientific reports of its use 
in equine tendinitis.  
Intralesional medications  
(1) Polysulfated glycosaminoglycans (PSGAGs) – PSGAGs have anti-inflammatory effects   
through inhibition of collagenases, MMPs and macrophage infiltration. A recent study 
evaluating intra-lesional PSGAG injection in a collagenase-induced SDF tendinitis model 
in horses showed histological improvement in collagen fiber organization at 5 months 
post-injury (Moraes et al. 2009). However, a clinical retrospective study showed no 
difference in re-injury rates in horses treated with PSGAGs when compared to control 
horses (Ely et al. 2009).  
(2)  Hyaluronan – sodium hyaluronan has been administered peritendinously and 
intralesionaly in tendinitis. One study showed histologic improvement and gross 
reduction in adhesion formation between DDFT and tendon sheath in collagenase-
induced model of intra-synovial tendinitis (Gaughan et al. 1991). However, a 
collagenase-induced model of mid-cannon SDF tendinitis reported no improvement in 
ultrasonographic properties, biochemical parameters or biomechanical strength, with 
increased inflammation histologically following treatment with hyaluronan (Foland et al. 
1992). In addition, a clinical retrospective study showed no significant difference 
between re-injury rates of horses treated with intralesional hyaluronan when compared to 
those treated conservatively (Ely et al. 2009).  
(3)  Beta-aminopropionitrile fumerate (BAPN) – intralesional BAPN inhibits lysyl 
oxidase, to prevent the formation of crosslinks between collagen fibers and promote 
better alignment of newly formed collagen. One study showed improved 
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ultrasonographic appearance and histological collagen alignment in BAPN-treated horses 
in a collagenase-induced model of SDF tendinitis (Dahlgren, Nixon & Brower-Toland 
2001). In addition, long term follow-up results of horses with SDF tendinitis treated with 
BAPN showed reduced risk of reinjury. However, a recent in vitro study reported altered 
morphology of tendon fibroblasts in addition to decreased collagen synthesis in tendon 
explants following culture with BAPN, suggesting a delay in tendon healing (Dahlgren, 
Nixon & Brower-Toland 2001).   
(4) Platelet-rich plasma (PRP) - platelet-rich plasma, an autologous concentrate of blood 
platelets has been introduced recently in humans for treatment of tendon injuries. 
Platelets are thought to influence healing by releasing growth factors such as platelet-
derived growth factor (PDGF), VEGF, TGF-β and IGF-I at the site of injury, influencing 
cell migration, proliferation, and matrix synthesis (Anitua et al. 2005). An in vitro study 
reported increased expression of collagen type I, type III and COMP mRNAs in equine 
SDFT explants cultured with PRP when compared to whole blood or serum (Schnabel et 
al. 2007). Increased concentrations of TGF-β1 and PDGF were also measured. A recent 
in vivo study in horses showed improved biomechanical properties, histologic 
organization and increased biochemical composition, 6 months post-injury, in a 
mechanically-induced SDF tendonitis model treated with PRP (Bosch et al. 2010). 
 
Surgical Management of Tendinitis 
Superior/Proximal check ligament desmotomy  
         Desmotomy of the accessory ligament of the SDFT (DALSDFT) as a treatment for 
SDF tendinitis is performed to increase the length of the myotendinous unit and reduce strain 
 23 
on the SDFT. Initial results demonstrated 70% of horses with SDF tendinitis treated with 
DALSDFT competed in at least two races without recurrent tendinitis. One study conducted 
in Standardbred racehorses reported 86% of horses treated with DALSDFT for SDF 
tendinitis returned to performance with 75% completing at least 5 starts (Hogan, Bramlage 
1995). Another study conducted in Standardbred racehorses showed similar results, however 
also reported the 12.5% incidence of suspensory desmitis as a consequence of this procedure 
(Hawkins, Ross 1995). A prospective study conducted in 127 Thoroughbred racehorses 
showed no significant difference between DALSDFT and conservative management with 
reference to return to performance and recurrence of injury (Gibson, Burbidge & Pfeiffer 
1997). 
Annular ligament desmotomy  
         Transection of the palmar annular ligament (PAL) is recommended when enlargement 
of the distal SDFT occurs and causes constrictive impingement by the PAL, preventing 
gliding function and further exacerbating the tendinitis.    
Tendon splitting  
         Early reports have described tendon splitting to improve blood flow to damaged tendon 
lesions that are relatively avascular (Stromberg, Tufvesson & Nilsson 1974). The aim of 
tendon splitting in acute tendinitis is to evacuate serum or hemorrhage. One study showed 
faster resolution of the core lesion, revascularization and increased collagen deposition in a 
collagenase-induced acute tendinitis treated with tendon splitting when compared to controls 




Novel Therapeutic Approaches for Tendon Regeneration 
         Complete regeneration is never achieved after tendon injury. More recent therapeutic 
developments are aimed at influencing the process of healing towards formation of 
physiologic and functional tissue. This has been attempted through the 
manipulation/application of various growth factors, use of cell-based approaches and gene 
therapy. 
Use of growth factors in tendon healing 
         Growth factors and other cytokines stimulate cell proliferation and chemotaxis, 
influence angiogenesis, and induce cell differentiation. They also regulate metabolic 
activities of cells, leading to synthesis and secretion of ECM components. Several growth 
factors influence tendon healing and have been used in both, in vitro and in vivo models of 
tendon repair. These factors include VEGF, IGF-I, PDGF, FGF-2 and TGF-β. 
         VEGF regulates angiogenesis by breaking down vascular basement membranes, 
expression of α-integrins, vasodilatation and increased vascular permeability, and endothelial 
cell proliferation and monocyte migration. In tendons, VEGF is expressed in tendon sheath 
fibroblasts and its expression increases in early healing process (Jackson et al. 1997, Bidder 
et al. 2000). Therapeutically, intralesional injections of VEGF in a murine model of Achilles 
tendinopathy resulted in significant increases in tensile strength during the early course of 
healing (Zhang et al. 2003). In addition, VEGF also caused a significant increase in 
expression of TGF-β1 in the early repair stages when compared to the controls. 
          Transforming growth factor- β1 is released from platelets, lymphocytes, macrophages, 
endothelial cells and fibroblasts and stimulates chemotaxis, angiogenesis and transcription of 
extracellular matrix genes. Despite its beneficial effects, it is implicated in fibrous tissue 
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formation from excessive deposition of disorganized collagen. In vitro, TGF- β1 induces 
collagen type I production by tenocytes (Klein et al. 2002). Further, inhibition of TGF- β 
activity reduces scar formation by limiting excessive collagen formation and improves 
tendon healing. The addition of TGF- β neutralizing antibodies in healing flexor tendons of 
rabbits increased the range of motion when compared to controls (Chang et al. 2000). Current 
studies are investigating the efficacy of gene therapy strategies to cause sustained 
neutralization of TGF- β. 
         Insulin-like growth factor- I has been studied for its effects on tendon healing. The 
primary effect of IGF-I on tendon healing is through its mitogenic effect, stimulating 
tenocyte proliferation at the site of injury. Exogenously applied IGF-I stimulates replication, 
collagen and proteoglycan synthesis in healthy rabbit flexor tendons (Abrahamsson, 
Lundborg & Lohmander 1991). In an equine collagenase-induced SDF tendonitis model, 
intralesional injections of IGF-I resulted in reduced lesion size, increased cell proliferation 
and collagen synthesis, and a trend toward increased mechanical strength in treated tendons 
when compared to control tendons (Dahlgren et al. 2002). A detailed description of IGF-I, its 
function and effects, and clinical use in tendon healing is provided below. 
         PDGF acts as chemoattractant and mitogen for fibroblasts and endothelial cells. PDGF 
may exert some effects through IGF-I as it up-regulates IGF-I and its receptors in target cells. 
An in vitro study showed PDGF stimulates collagen, proteoglycan, and DNA syntheses in 
tenocytes (Yoshikawa, Abrahamsson 2001). In addition, a recent study utilizing a canine 
flexor tendon injury model showed improved functional properties and increased collagen 
synthesis with the use of controlled delivery of PDGF when compared to controls 
(Thomopoulos et al. 2009). 
 26 
          Fibroblast growth factor-2 stimulates angiogenesis and proliferation of fibroblasts. 
Application of exogenous FGF-2 accelerated healing of human patellar tendon in an in vitro 
model (Chan et al. 1997). This was consistent with in vivo studies showing FGF-2 injected 
intralesionally into healing patellar tendons in rats increased cell proliferation and collagen 
type III synthesis (Chan et al. 2000). A more detailed description of FGF-2 and its effects is 
provided further on.  
Cell-based therapies for tendon regeneration 
         Stem cell therapy, especially the use of postnatal/adult tissue-derived mesenchymal 
stem cells (MSCs), is a recent focus of research in tendon healing.  Following tendon injury, 
a cascade of inflammatory cells takes place. Cells involved in the synthesis of new tissue are 
present locally but comprise a very small component of the tissue (Richardson et al. 2007a). 
Further, this progenitor cell population varies with the functional properties of tendon and 
decreases with the age of tendon. Multiple sources of MSCs have been used for tendon 
regeneration. A brief review of various sources of MSCs used for the treatment of equine 
SDF tendinitis is provided below. 
         Empirically, MSCs from bone marrow have been used in equine SDF tendinitis with 
documented beneficial outcomes (Frisbie, Smith 2010, Koch, Berg & Betts 2009). 
Implantation of autogenous bone marrow MSCs (BMMSCs) as a potential therapeutic option 
for spontaneously occurring SDF tendinitis core lesions in performance horses was first 
described in 2003 (Smith et al. 2003). This case demonstrated the feasibility of the technique 
and reported no adverse reactions up to 6-weeks post injection.  A later study determined the 
fate of these injected cells in experimentally-induced tendon lesions and reported successful 
integration into adjacent healthy tendon (Guest, Smith & Allen 2008). Since then, a number 
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of experimental and case-based studies have been performed to determine the usefulness of 
MSCs in horses. One study evaluated the effect of BMMSCs in 11 spontaneously occurring 
lesions of the SDFT in race horses in comparison to control horses (Pacini et al. 2007). In 
MSC-injected cases, there was an improvement in ultrasonographic scores and return to 
performance in 81% of horses with no incidence of re-injury up to 2 years following 
treatment. In contrast all control horses re-injured the SDFT within 4 to 12 months. Another 
retrospective study evaluated the use of BMMSCs in spontaneously occurring SDF tendinitis 
in 168 horses followed by rehabilitation with long term follow-up (Smith 2008a). This study 
reported successful return to function in all treated horses with occurrence of re-injury in 
only 13% of horses up to one year, and 23-43% in more than 1 year follow-up. Overall, the 
re-injury rate for the MSC-treated horses was 24%, which was significantly reduced 
compared to 56% incidence of re-injury in conventionally managed horses (Dyson 2004) 
         Adipose derived-nucleated cells have also been evaluated for treatment of equine tendon 
regeneration due to ease of collection, minimal donor-site morbidity and faster recovery of 
cells due to absence of a cell culture step (Richardson et al. 2007a). One study reported 
histologic improvement of collagenase-induced SDF tendinitis in horses treated with 
adipose-derived cells, when compared to control horses (Nixon et al. 2008). An 
immunomodulatory function of these cells was suggested in the healing process due to 
reduced infiltration of inflammatory cells. Another study evaluated the effects of autogenous 
adipose-derived cells dispersed in PRP as a biologic scaffold in spontaneously occurring 
SDFT core lesions in horses (Del Bue et al. 2008). This study reported favorable results with 
return to function in 87% of treated horses.     
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         Alternative sources of cell-based therapies for tendon regeneration have been described 
in other species in experimental models. Synovial MSCs have been described in Achilles 
tendinopathy studies and were shown to stimulate superior healing of tendon-bone interfaces 
with improved fiber alignment (Ju et al. 2008). Another study reported improvement in 
histologic structure and tensile strength with use of dermal fibroblasts used to treat a porcine 
model of SDF tendon lesion (Liu et al. 2006). Autologous tenocytes engineered onto 
polyglycolic acid fibers were shown to provide superior healing in avian model of SDF 
tendon defect with improved histologic structure (Cao et al. 2002). More recently, embryonic 
stem cells have been described as a potential source of cells. A recent study, demonstrated 
better mechanical strength and histologic structure in a murine model of patellar 
tendinopathy treated with human embryonic stem cells, when compared to controls (Chen et 
al. 2009). 
Gene therapy 
         The delivery of exogenous genes to injured tendon is a relatively new approach of 
enhancing tendon healing. Transfer of growth factor cDNAs provides a means of sustained, 
prolonged expression of therapeutic proteins. In vitro adeno-associated virus-mediated gene 
transfer of bFGF in tendon explants showed effective delivery to tenocytes and significantly 
increased expression of collagen type I and type III gene expression (Wang et al. 2005). 
Modification of murine tenocytes with VEGF expression constructs has been shown to 
increase the levels of expression of TGF-β, collagen type I and type III (Wang, Liu & Tang 
2005). Similar results were obtained with exogenous PDGF gene transfection (Wang, Liu & 
Tang 2004). 
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          In addition, this technique can be used as a tool for delivering growth factor-enhanced 
MSCs. One study showed IGF-I-enhanced MSCs resulted in histologic and biomechanical 
improvement in a collagenase-induced SDF tendinitis in horses, when compared to control 
(Schnabel et al. 2009). Another study evaluating the effect of BMMSCs transfected with 
TGF-β1 gene in a lupine model of Achilles tendinopathy showed higher concentrations of 
collagen type I protein and larger fiber bundle formation at the site of injury (Hou et al. 2009, 
Fu, Wong & Chan 1999). Bone morphogenetic protein-12 is involved in tenogenesis and 
tendon healing, and stimulates increased collagen type I expression (Seeherman et al. 2008). 
Recently, an in vitro BMP-12 transfection study conducted in equine BMMSCs and SDF 
tenocytes resulted in high BMP-12 and COMP expression (Murray, Santangelo & Bertone 
2010). This study suggested the possible use of BMP-12-tranduced BMMSCs for tendon 
repair. 
 
Fibroblast Growth Factor-2 (FGF-2) 
         FGF-2, also known as basic fibroblast growth factor (bFGF), is a member of the 
heparin-binding growth factor family. It is an 18-kd, 146-amino acid, single chain 
polypeptide, although larger forms are also present. FGF-2 binds to heparin and heparan-
sulfate proteoglycans on cell surfaces and in the extracellular matrix. Following ECM 
degradation, FGF-2 is released and then binds to one of four specific cell surface receptors 
(FGFRs 1-4). FGFRs are cell surface tyrosine kinase receptors, which then initiate further 
signaling (Hsu, Chang 2004). Physiologically, FGF-2 is produced by endothelial cells, 
fibroblasts, smooth muscle cells, chondrocytes and mast cells, and acts on a wide variety of 
cells involved in biological processes, including development, differentiation, cell 
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proliferation and angiogenesis. In wound healing, FGF-2 causes proliferation and migration 
of keratinocytes. It causes fibroblasts to produce collagenase and stimulates proliferation of 
capillary endothelial cells, which are important for initiation of angiogenesis. Finally, it also 
helps in the formation of granulation tissue.  
 
Mechanisms of FGF-2-induced responses in MSCs  
         The molecular mechanisms involved in the regulation of MSC proliferation and 
differentiation by bFGF have been addressed in several studies. Long term sub-culture of 
MSCs is decreased in vitro due to increased mRNA expression level of TGF-β. TGF- βs 
arrest the cell growth of epithelial cells and blood cells in G1 phase through inhibition of G1 
cyclin-dependent kinases (CDKs). FGF-2 suppresses cellular senescence of human MSCs by 
down regulating TGF- β2 (Ito et al. 2007, Ito et al. 2008).   
         More recently, another study showed that FGF-2 induces transient activation of c-Jun 
N-terminal kinase (JNK). JNK signaling mediates FGF-2-induced stimulation of proliferation 
and maintenance of differentiation potential of human BMMSCs (Ahn et al. 2009). In brief, 
FGF receptor substrate 2 (FRS2) is a critical component of FGF signaling and is activated by 
FGF receptors. FRS2 recruits growth factor receptor-bound protein-2 (Grb2) and activates 
the Ras-Raf-mitogen-activated-protein kinase (MAPK) signaling pathway. MAPK signaling 
cascades are in turn mediated by JNK which is one of the signal transducers for growth 
factors.  
Use of FGF-2 in progenitor cell culture systems     
         FGF-2 has been used in many cell culture systems to stimulate proliferation and 
maintain self renewal capacity of multiple types of stem/progenitor cell populations which 
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include BMMSCs, adipose-derived cells, and embryonic stem cells. Previous studies have 
shown that FGF-2 enhances the growth of MSCs and maintains their multilineage differential 
potential during in vitro expansion (Solchaga et al. 2005, Bianchi et al. 2003). Increased 
proliferation and maintenance of the undifferentiated state during in vitro expansion is 
important for MSC applications in cell-based tissue repair. Many studies have shown that in 
vitro expansion of bone marrow-derived MSCs with FGF-2 supplementation stimulates 
proliferation and delays loss of chondrogenic potential (Solchaga et al. 2010, Stewart et al. 
2007). Similar effects on proliferation and maintenance of self-renewal by FGF-2 were 
demonstrated in human embryonic stem cells and adipose-derived cells (Eiselleova et al. 
2009, Lee et al. 2009). Based on the available evidence, the effect of FGF-2 on monolayer 
expansion of equine tendon-derived cells was evaluated in this study and compared to FGF-
2’s effects on bone marrow-derived cells.  
 
Insulin-like Growth Factor-I 
         Insulin-like growth factor-I (IGF-I), referred to originally as ‘sulfation factor’ and 
‘somatomedin’, was later renamed IGF-I due to its structural homology with human 
proinsulin. IGF-I has autocrine and paracrine effects, stimulating anabolic responses in target 
cells by binding to type I IGF receptor (IGF-IR), a cell surface tyrosine kinase receptor. This 
leads to a complex signal transduction pathway, resulting in modulation of gene expression 
and anabolic responses within the cell (Dahlgren, Mohammed & Nixon 2006). The 
bioavailability of IGF-I is regulated by IGF binding proteins (IGFBPs), comprising six 
structurally related proteins with a high affinity for IGF-I. IGFBPs inhibit the activity of IGF-
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I by restricting its access to IGF-IR, and also protect IGF-I from pericellular proteases and 
consequently increasing its extracellular half-life. 
Cellular mechanisms of IGF-I activities 
         The primary physiologic role of IGF-I is mitogenesis. Some studies explained this 
mitogenic capacity through activation of phosphatidylinositol 3-kinase (PI3K)/Akt and 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 
pathways. Both signaling pathways promote G1/S cell cycle progression leading to increased 
proliferation (Mairet-Coello, Tury & DiCicco-Bloom 2009). Hypoxia/anoxia-induced 
apoptosis has been shown to be a cause of tenocyte death in chronic tendinopathy (Birch, 
Wilson & Goodship 1997). One study showed prosurvival effect of IGF-I on Achilles tendon 
cells by activation of protein kinase B (PKB) which prevents cell death by phosphorylating 
various cytoplasmic and nuclear targets (Scott, Khan & Duronio 2005) 
Effects of IGF-I on tendon healing 
         IGF-I has been extensively studied over the last decade, with respect to its effects on 
tendon regeneration.  Expression of IGF-I is increased in tendon healing as described earlier. 
A recent in vivo study showed increased expression of IGF-I and IGFBPs following 
mechanical loading in a murine model (Olesen et al. 2006). Further, this study also showed 
increased expression of mechano-growth factor (MGF), a splice variant of IGF-I, which is 
more rapidly up-regulated after loading when compared to IGF-I.  Initial in vitro studies 
showed increased matrix synthesis and cell proliferation following IGF-I supplementation of 
tendon explant cultures (Abrahamsson, Lundborg & Lohmander 1991). 
         In vivo effects of IGF-I on tendon healing have also been evaluated. Intralesional 
injection of IGF-I into healing SDF tendon in an equine collagenase-induced tendinitis model 
 33 
resulted in increased cell proliferation and collagen content, and a trend towards improved 
mechanical strength in treated tendons when compared to controls. This study also showed 
improvement in ultrasonographic scores and a reduced lesion size (Dahlgren et al. 2002). In 
addition, a gene therapy approach using IGF-I transfected BMMSCs in an equine 
collagenase-induced SDF tendinitis model showed improvement in histologic structure and a 
trend towards increased mechanical strength (Schnabel et al. 2009)) 
 
Mesenchymal Stem/Progenitor Cells 
         A stem cell is an unspecialized cell that is capable of replicating or self renewing itself 
and developing into specialized cells of a variety of cell types. Adult stem cells, like all stem 
cells, share at least two characteristics. First, they can make identical copies of themselves 
for long periods of time; this ability to proliferate is referred to as self-renewal. 
Second, they can give rise to mature cell types that have characteristic morphologies and 
specialized functions. Typically, stem cells generate an intermediate cell type or types before 
they achieve their fully differentiated state. The intermediate cell is called a precursor or 
progenitor cell. Bone marrow consists of two populations of stem cells, which are 
hematopoietic stem cells, responsible for formation of all types of blood cells and the oldest 
recognized population of stem cells, and bone marrow stromal cells, which is a mixed cell 
population that generates bone, cartilage, fat, fibrous connective tissue, referred to as the 
mesenchymal stem cells, and was described shortly after. Since then, the presence of 
stem/progenitor cell populations has been described in a number of specialized tissues which 
includes, endothelium, nervous system, epithelial precursors in skin and digestive system, 
pancreas and liver, skeletal muscle, and dental pulp progenitor cells to name a few.  
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Bone marrow-derived MSCs  
         Bone marrow-derived MSCs undergoes physiologic differentiation through the 
mesengenic process into other phenotypes which includes cartilage, bone marrow, muscle, 
bone, tendon and ligament to maintain tissue homeostasis (Caplan 2005b, Caplan 2007b). 
Bone marrow-derived MSCs have been used extensively in cell-based reconstructive therapy 
in orthopedic injuries over the last decade with promising results (Wakitani et al. 2002b). 
Cartilage repair in osteoarthritis has been attempted in both human and veterinary patients 
with autogenous bone marrow-derived MSCs and has shown improvement in arthroscopic 
and histological grading scores (Wakitani et al. 2002a, Frisbie et al. 2009). Autogenous bone 
marrow derived-MSCs along with matrix composites have been used in promising resolution 
of critical segmental bone defects (Quarto et al. 2001).  
         Later studies have demonstrated the use of bone marrow-derived MSCs for tendon 
repair with beneficial effects. In vivo case-based studies in horses treated with autogenous 
bone marrow-derived MSCs have shown return to performance and reduced incidence of re-
injury as described earlier (Pacini et al. 2007, Smith 2008a). However, bone marrow-derived 
MSCs are shown to be heterogeneous group of cells that contain subpopulations of tissue-
committed progenitor cells or primitive pluripotent stem cells which may have a harmful 
effect on its use in tissue specific regeneration (Kucia, Ratajczak & Ratajczak 2005). One 
study reported formation of ectopic bone in a lupine model of tendon defect treated with 
autogenous bone marrow-derived MSCs demonstrating faulty repair (Dressler, Butler & 
Boivin 2005). In addition to this a significant variation in bone marrow-derived MSCs exists 
between subjects among different age groups.   
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Tendon-derived Progenitor Cells   
         Recent studies have led to the discovery of progenitor/stem cell populations in tendons 
based on the fact that tendons are derived from mesenchymal cells that also give rise to bone, 
cartilage, fat and muscle. First report of existence of MSCs in tendon tissue was made in 
2003 (Salingcarnboriboon et al. 2003). This study reported the development of tendon-
derived cell lines in transgenic mice which had enhanced proliferation in vitro with FGF-2 
treatment. In addition, these cell lines expressed tendon-phenotype related genes, which 
included scleraxis, COMP, and type I collagen. More recently, another study identified a 
unique cell population, termed tendon stem/progenitor cells (TSPCs) within the tendon 
extracellular matrix-niche and demonstrated universal stem cell characteristics, which 
include clonogenecity, multipotency and self-renewal capacity from both mouse and human 
tendon samples (Bi et al. 2007). A previous study from our lab compared equine tendon-, 
muscle-, and bone marrow-derived cells and showed that tendon-derived cells yielded higher 
cell numbers following isolation in comparison to bone marrow-derived MSCs with 
significantly greater biosynthetic capacities (Stewart et al. 2009a).  
Characterization of tendon-derived progenitor cells  
         Charaterization of tendon-derived progenitor cells have been performed in mouse and 
human samples and shown to express higher amounts of tendon-lineage specific markers like 
scleraxis, a twist-related bHLH transcription factor, COMP, the transcription factor SOX9 
(Sox9), and osteogeneic transcription factor runt-related transcription factor 2 (Runx2) and 
tenomodulin, a cell surface marker for tenocyte proliferation and maturation when compared 
to bone marrow-derived MSCs (Bi et al. 2007). A recent attempt to characterize rat tendon-
derived progenitor cells, performed flow cytometric analysis for MSC markers and showed 
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88-99% of these cells were positive for stem cell marker, CD44 and fibroblastic marker, 
CD90 (Rui et al. 2010). In addition, these cells were negative for hematopoietic stem cell 
marker, CD34 and for endothelial cell marker, CD31 confirming absence of contaminating 
hematopoietic cells and endothelial cells. The same study also showed expression of 
tenogenic markers like α-SMA, tenascin C, tenomodulin and aggrecan in rat tendon-derived 
cells. In addition, these cells did not express collagen type I at passage 0 (P0) and P3 and 
collagen type II at P0. Immuno-histochemical staining of human tendon-derived cells was 
positive for D7-FIB, a fibroblast-marker that maintained through multiple passages (de Mos 
et al. 2007a).      
Multipotency of tendon-derived progenitor cells  
         Multipotency has been confirmed by differentiation towards osteogeneic, chondrogenic 
and adipogenic lineages. Many studies have performed differentiation experiments in mouse, 
rat and human species and reported successful differentiation towards all three lineages (Bi et 
al. 2007, Salingcarnboriboon et al. 2003, Rui et al. 2010, de Mos et al. 2007a). In addition, 
the differentiation capacity of tendon-derived was greater in comparison to bone marrow-
derived MSCs with a higher osteogeneic and adipogenic capacity (Bi et al. 2007). 
In vivo effects of tendon-derived progenitor cells  
         Tendon-derived progenitor cells have been evaluated minimally in two studies in 
experimental murine models (Bi et al. 2007, Salingcarnboriboon et al. 2003). One study 
implanted sheets of tendon-derived cells in an experimentally created murine patellar tendon 
defect (Salingcarnboriboon et al. 2003). Successful incorporation was determined on 
histology 3 months after implantation. Another study evaluated in vivo osteogenesis of BMP-
2 expanded tendon-derived cells by injecting with hydroxyapatite/tricalcium phosphate 
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carrier subcutaneously in immune-suppressed mice (Bi et al. 2007). Bone formation was 
observed after 8 weeks, along with tendon-like tissue in adjacent areas confirmed by the 
presence of unique collagen fibers when the tissue was visualized under polarized light.  
          
Preplating Technique 
         Currently several methods are used to isolate and purify mesenchymal stem/progenitor 
cells for use in cell-based tissue repair due to their heterogeneous nature. Some of them 
include magnetic cell sorting, fluorescent activated cell sorting (FACS) and the preplating 
technique. Magnetic cell sorting and FACS are both cell surface marker-dependent 
techniques that isolate homogenous populations of stem/progenitor cells based on presence 
of MSC specific marker proteins on the cell surface. Immunomagnetic isolation technique 
has been reported to be used in isolating osteoprogenitors from human BMMSCs (Encina, 
Billotte & Hofmann 1999). FACS has been use to isolate mesenchymal progenitor cells from 
human, rat and mouse bone marrow (Bi et al. 2007, Scutt, Rolf & Scutt 2008).  
         However marker profile-dependent isolation methods are limited as they rely on the 
expression of cell surface marker proteins that are variable and change under cell culture 
conditions. These techniques also do not take into consideration behaviors such as cell 
survival, proliferation rates and multipotency in vivo and in vitro. Further, marker profile-
dependent isolation methods are not feasible to isolate progenitor cell populations in species 
that do not have specified cell surface markers and established genotype databases. 
          A marker profile-independent method, known as the preplating technique has been 
described and evaluated for isolating myoblasts, a progenitor cell population in skeletal 
muscles (Gharaibeh et al. 2008). This technique involved culturing digested muscle tissue for 
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a set period of time to allow the fibroblastic cell fraction to attach while transferring the 
supernatant containing the myogenic fraction onto a new plate, thus separating the desired 
cell fraction. This step was repeated at 12-24 hour intervals for 5 consecutive days to give 
rise to cells fractions in preplate 0 (PP0) on day 0 to preplate 6 (PP6) on day 5.   
         Progenitor cells obtained via the preplating technique have been characterized and the 
technique validated by comparing with FACS and magnetic cell sorting. The first cells to 
adhere during the early stages of the preplating technique are known as the rapidly adhering 
cell (RAC) fraction and have been shown to be comprised of mostly fibroblast-like and 
myoblast cells. Cells isolated from the later stages of preplating contain muscle-derived stem 
cells and are known as slowly adhering fraction (SAC). One study showed increased 
immunochemical expression of desmin, a marker specific to myogenic cells in later 
preplates, PP4-PP6 ranging from 75-94% as compared to 5-37% in PP1-PP3 (Jankowski et 
al. 2001). Flow cytometric analysis of the PP6 cell fraction in the same study showed 
expression of surface proteins like Sca-1, CD34 and c-Kit, markers all specific to myogenic 
population. Another study compared magnetic cell sorting and preplating to purify human 
myoblasts (Park, Moon & Kim 2006). This study reported 83% increase in desmin positive 
cells from primary culture to PP5, as compared to 21% primary culture and positive selection 
of myoblasts by magnetic cell sorting increased from 30% to 42%. 
          Based on the evidence summarized above, this study aimed at isolating a progenitor 
cell population from the lateral digital extensor tendon of horses for cell-based therapies in 
tendon regeneration using the preplating technique and comparing with bone marrow-derived 
mesenchymal cells with reference to cell viability, tendon gene expression and matrix 
synthesis in an in vitro three dimensional model of tendon healing.  
 39 
In vitro Models of Tendon Regeneration 
         Lack of successful outcomes with existing treatment options for equine tendinitis has 
led to constant efforts in developing novel approaches of tendon regeneration with cell-based 
therapies to improve biomechanical strength. Various in vitro and in vivo models of tendinitis 
are described for evaluating the efficacy for these novel approaches. Most widely used in 
vivo-models of equine tendinitis include the collagenase-induced model and the mechanical 
model (Nixon et al. 2008, Dahlgren et al. 2002, Schnabel et al. 2009, Bosch et al. 2010). 
However, in vivo models are expensive, more labor intensive and involve ethical concerns to 
research animals. In addition, an in vitro screening step is omitted in many new therapies 
being evaluated, and assessing the need to carry out an in vivo evaluation in only promising 
therapies.   
         Acellular tendon has been used in tissue-engineering studies to develop a construct for 
an appropriate scaffold material for reseeding in cell-based approaches for flexor tendon 
injuries in lupine models with a goal of therapeutic use in humans (Zhang et al. 2009, Chong 
et al. 2009). Acellularization of tendons was carried out in these studies by freeze-thaw 
cycles followed by treatment with trypsin. One study comparing tenocytes and mesenchymal 
stem cells for reseeding of lupine acellular flexor tendon showed adherence of both cell types 
used and viability of cell-acellular construct up to 1 week in vitro (Kryger et al. 2007). A 
previous study from our lab used autogenous acellular tendon prepared as sheets of 1 cm X 1 
cm from equine superficial digital flexor tendon as an in vitro model to compare tendon-, 
muscle- and bone marrow-derived cells with reference to cell adherence and viability, tendon 
gene expression and viability (Stewart et al. 2009a). Although viability of the cell types used 
to the acellular tendon was confirmed on histology, adherence and proliferation was possible 
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only to the surface of the acellular tendon, which does not simulate conditions present in vivo 
where cells are dispersed in the tendon matrix that contains bundles of collagen fibers.      
Hence, autogenous acellular pulverized superficial digital flexor tendon is used in this study 
to provide a 3-dimensional matrix model to evaluate adherence and viability of equine 
tendon- and bone marrow-derived cells expanded in monolayers with or without FGF-2 
supplementation. 
 
Objectives and Hypothesis 
         The objective of this study was to determine whether FGF-2 supplementation during 
monolayer expansion can enhance the proliferative capacity and matrix synthesis of both 
tendon- and bone marrow-derived cells.  Secondly, this study evaluated whether IGF-I 
supplementation alone or following FGF-2 monolayer expansion would have a beneficial 
effect on cell viability, tendon gene expression, and  matrix synthesis of tendon- and bone 
marrow-derived cells cultured with tendon matrix. For this study our laboratory utilized 
differential adherence pre-plating technique to isolate tendon-derived cells previously 
described to isolate progenitor cells from muscle. Bone marrow-derived progenitor cells were 
used as the current source for cell-based tendinitis therapy. My hypothesis was that tendon-
derived cells expanded with FGF-2 followed by IGF-I supplementation with tendon matrix 
will have an increased cell viability/ proliferation, tendon gene expression, and matrix 
synthesis when compared to bone marrow-derived cells with or without growth factor 
cultured under similar conditions. 

















Figure 2: Representation of hierarchical structure of equine superficial digital flexor tendon 











Figure 3: Photomicrograph of equine superficial digital flexor tendon stained with 










Figure 4: Photomicrograph of equine superficial digital flexor tendon stained with picro-
sirius red under polarization light showing characteristic crimp pattern of collagen fibers.  




MATERIALS AND METHODS 
 
 
Collection of Samples  
         Bone marrow and tendon were collected aseptically from six horses (two to four years 
of age) euthanized for reasons unrelated to musculoskeletal disease. All samples were 
obtained in accordance with guidelines reviewed and approved by the Institutional Animal 
Care and Use Committee. All horses were sedated with 0.01 to 0.03 mg/kg of detomidine 
administered IV via a jugular catheter. Following collection of the bone marrow aspirates, all 
horses were euthanized by an intravenous injection of sodium pentobarbital (104mg/kg). The 
tendon specimens were collected immediately following euthanasia.   
 
Progenitor Cell Culture                                                                                                                                      
Processing of bone marrow-derived cells 
          Sternal bone marrow aspirates were collected using Jamshidi needles a (Schnabel et al. 
2009).  Approximately 15-20 mLs of bone marrow was aspirated into syringes containing 
1,000 units of heparin. Each bone marrow aspirate was diluted with 15 mL of PBS solution 
and centrifuged at 300 X g for 10 minutes. The supernatant was removed, the pellet was 
resuspended in PBS solution, and centrifugation was repeated. Pelleted cells were 
resuspended in 12 mL of low-glucose DMEMb supplemented with 10% fetal bovine serumc, 
300 µg of L-glutamined/mL, 100 U of sodium penicilline/mL, and 100 µg of streptomycin 
sulfatee/mL. Resuspended cells were placed in a 75 cm2 flaskf and incubated at 37oC in a 5% 
carbon dioxide atmosphere with 90% humidity. The bone marrow-derived cells were 
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passaged after they reached focal confluence. The cells were monolayer expanded in culture 
medium supplemented with or without 100 ng FGF-2g/mL for two passages which provided 
sufficient cells for subsequent experiments. Time to confluence and cell counts at 
trypsinization were recorded. 
Processing of tendon-derived cells  
        The lateral digital extensor tendon from a hind limb was harvested aseptically from each 
horse. A 4-cm x 1-cm sample of tendon was reserved for cell isolation. The specimen for cell 
isolation was diced into 0.25 cm3 pieces and digested for 16 hours at 37°C in 0.2% 
collagenaseh high-glucose DMEM supplemented with 1% FBS, 100 U of sodium 
penicillin/mL, and 100 µg of streptomycin sulfate/mL. Following digestion, the isolated cells 
were passed through a 40 µm filteri. The isolated cells were collected by centrifugation at 300 
X g for 5 minutes. The supernatant was removed and the cell pellet was resuspended in 
media. Cell viability was determined by the use of exclusion of trypan blue dye j (O'Brien, 
Gottlieb-Rosenkrantz 1970). 
Tendon-derived cell culture 
         Progenitor cells were collected from tendon by use of a previously described protocol 
(Stewart et al. 2009a, Gharaibeh et al. 2008). Tendon-derived cells were seeded at 13,300 
cells/ cm2 in culture flasks  in high-glucose DMEM supplemented with 20% FBS, 300 ug of 
l-glutamine/mL, 100 U of sodium penicillin/mL, and 100 ug of streptomycin sulfate/mL. The 
slowly adherent, tendon-derived cells were preferentially isolated from the rapidly adherent, 
fibroblast-like cells by differential attachment. The culture medium and unattached cells were 
serially transferred to fresh culture flasks every 24 hours during the first 6 days of culture 
(Stewart et al. 2009a). The tendon-derived cells that adhered on day 6 of the transfer protocol 
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were maintained until confluence and expanded in monolayers with or without 
supplementation of FGF-2 (100ng/mL) for two passages to generate sufficient cells for 
subsequent experiments.  
 
Tendon Matrix Culture Model  
         Superficial digital flexor tendons were collected from donor horses and pulverized in a 
freezer millh under liquid nitrogen. The pulverized tendon was subjected to four rounds of 
freeze-thaw cycles at -80°C and 4°C to kill the resident tenocytes. A 1 percent (mass/volume) 
acellular tendon matrix suspension was prepared with tenogenic medium (high-glucose 
DMEM supplemented with 10% fetal bovine serum, 300 µg of L-glutamine/mL, 100 U of 
sodium penicillin/mL, 100 µg of streptomycin sulfate/mL, and 37.5µg/mL ascorbic acid). 
The tendon matrix suspension was maintained in culture without additional cells to serve as a 
negative control (matrix only), or seeded with 250,000-cell aliquots of the expanded tendon- 
and bone marrow-derived cells, supplemented with or without 100 ng IGF-Ii /mL, in 24-well 
ultra-low attachment culture plates.j This experimental design (Figure 5) comprised nine 
treatment groups. Each treatment group contained eighteen replicates. Twelve replicates were 
used for RNA isolation, three replicates were used for collagen synthesis, and three replicates 
were used for GAG synthesis. The replicates for each treatment group were averaged as one 
data point. This was repeated for each of the 6 horses included in the study. Each treatment 
well was supplemented with one mL of tenogenic medium containing 0 or 100 ng/mL of 
IGF-I. Fresh medium was added to all wells every two days after removal of the exhausted 
medium. All culture samples were collected on day 7 by separating the medium from the 
matrix with cells by centrifugation.  
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Cell Number 
         Three replicates of each treatment group were used to measure cell number on day 7, 
by use of an mitochondrial metabolic assayk as per manufacturer’s instructions. In brief, 50 
µL of the assay reagent containing tetrazolium was added to fresh medium in each well and 
the cells were incubated at 37oC for 2.5 hours. One hundred µL of medium from each well 
was transferred to a 96-well plate and absorbance was measured at 492nm in a microplate 
readerl to detect concentrations of the metabolic product, formazan. All samples were 
assayed in duplicates, and a mean value was calculated to provide a single data point. The 
optical density data were converted to ‘cell number’ by reference to standard curves 
generated from known numbers of tendon- and bone marrow-derived cell cultures. 
 
RNA Isolation and Gene Expression  
         Twelve replicates from each treatment group were pooled, snap-frozen in liquid 
nitrogen, and stored at -80˚C for RNA isolation. Total RNA was extracted using Trizolm 
reagent according to the manufacturer’s suggested protocol and purified in silica columns.n 
RNA concentration and purity were assessed by UV spectrophotometry and agarose gel 
electrophoresis respectively. One µg of RNA in each sample was converted to cDNA with a 
commercial reverse transcription kito and oligo(dT) primers. Target cDNAs were amplified 
via real-time PCR using Taq DNA polymerasep and gene-specific primers designed from 
available published sequences in Genbank, and a multiple sequence alignment program.q 
Primer specificity was confirmed by cloning and sequencing the PCR products (Appendix). 
Real-time quantitative PCR was performed in triplicate for collagen I, collagen III, and 
COMP mRNAs and the reference gene, elongation factor-1α (EF1α). A fluorescence 
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detection systemr was used to measure PCR-generated cDNA and generate threshold cycle 
values. All reactions were run as singleplex and the relative gene expression was quantified 
by use of the 2-∆∆CT method (Livak, Schmittgen 2001). 
 
Collagen Synthesis 
          Collagen synthesis was determined via [3H] proline incorporation according to a 
published protocol (Cechowska-Pasko, Surazynski & Bankowski 2009). On day 6, three 
wells of each treatment group were radiolabeled with 50 µCi of [3H] prolines/mL of 
tenogenic medium and incubated for 24 hours. The samples were washed three times with 
0.5mL of PBS containing 1mM Proline and stored at -80˚C. Radiolabeled samples were 
freeze-thawed three times, digested, and homogenizedt prior to RNase treatment. The total 
protein was precipitated with tricholoroacetic acid and washed three times with L-proline to 
remove traces of unincorporated [3H] proline. The resulting pellets were digested with 
purified collagenase,u and centrifuged at 3220Xg for 10 minutes. The supernatant and pellets 
were separated and transferred to scintillation liquid. Radioactivity was measured in a 
scintillation counter.v Newly synthesized collagen was detected on the basis of radioactivity 
in the sample supernatants following collagenase-digestion. 
 
Glycosaminoglycan (GAG) Synthesis 
         GAG synthesis was determined by measuring 35SO4 incorporation into each sample. 
Three wells of each treatment group were radiolabeled with 10 µCi of 35S labeled sodium 
sulfate/mLw during the last 24 hours of the experiments (Masuda, Shirota & Thonar 1994). 
The samples were washed three times with PBS and then digested in 1 mL of buffer 
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containing 0.5 mg of papainx at 65oC for 16 hours. Twenty-five µL aliquots of 35S-labelled, 
papain-digested samples were placed in multiwell punch plates,y precipitated with alcian blue 
dye, and counted by scintillation(Masuda, Shirota & Thonar 1994, Stewart et al. 2009b). All 
counts per minute (CPM) values were adjusted for decay of 35S-radioisotope from the time of 
radiolabeling to assay. Values were expressed as CPM per 250,000 cells. 
 
Statistical Analyses 
          Mean + SE for each statistic were calculated for each cell type and supplementation of 
FGF-2, IGF-1, and the combination of FGF-2 and IGF-1. Background values detected in the 
matrix-only group were subtracted from the values of the other groups for quantification of 
collagen and GAG synthesis. Cell number, collagen synthesis and GAG synthesis data were 
log-transformed for data normalization. The effect of cell type was analyzed using a Mixed 
Effects Model, with the subject as a random effect. Among the individual cell types (tendon- 
and bone marrow-derived cells), the effect of growth factor supplementations were evaluated 
using 2-way repeated-measures ANOVA to control for differences between horses. When 
group differences for growth factor supplementation were noted, pair-wise multiple 
comparisons were made using Holm-Sidak non-parametric test. A commercially available 


































Monolayer Cell Expansion  
             Overall, the mean cell number following monolayer expansion was significantly (P = 
0.011) higher in tendon-derived cells when compared to bone marrow-derived cells (Table 
1). Monolayer expansion of tendon-derived cells with FGF-2 significantly (P = 0.027) 
increased cell number when compared to the unsupplemented tendon-derived cultures 
(Figure 6). In contrast, monolayer expansion with FGF-2 did not significantly (P = 0.311) 
affect proliferation of bone marrow-derived cells. 
 
Cell Number  
          After seven days in culture with pulverized tendon matrix and IGF-I, there was no 
significant effect of cell type on mean cell number, as determined by mitochondrial 
metabolic assay (Figure 7). Monolayer expansion with FGF-2 did not significantly change 
the numbers of tendon- (P = 0.052) or bone marrow-derived (P = 0.096) cells cultured with 
tendon matrix. There was no significant (P = 0.178) effect of IGF-I supplementation on cell 
number for either cell type. The cell number of the “matrix only” control group was zero, 
confirming the absence of viable cells. 
 
Extracellular matrix gene expression  
         As expected, no mRNA was isolated from the acellular matrix samples, verifying that 
no viable endogenous tenocytes remained. Therefore, the gene expression data derived from 
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bone marrow-derived cells cultured with tendon matrix without growth factor 
supplementation (bone marrow-derived cells only) were used as reference values for 
comparative analyses.  
Collagen type I  
        Collagen type I mRNA expression in tendon-derived-cell groups and bone marrow-
derived-cell groups was not significantly different (P = 0.087) (Figure 8). Among the 
tendon-derived cell groups, supplementation with IGF-I did not significantly (P = 0.095) 
increase collagen type I mRNA expression. In the bone marrow-derived cell groups, IGF-I 
significantly (P = 0.028) increased collagen type I mRNA expression. Monolayer expansion 
with FGF-2 had no effect on subsequent collagen type I mRNA expression in either tendon- 
or bone marrow-derived cell types cultured with tendon matrix. 
Collagen type III mRNA expression 
          Overall, tendon-derived cell groups cultured with tendon matrix expressed 
significantly (P = 0.003) more collagen type III mRNA than bone marrow-derived cell 
groups (Figure 9). Within the tendon-derived cell groups, there was no significant effect of 
FGF-2 (P = 0.623) or IGF-I (P = 0.119) on collagen type III mRNA expression. In the bone 
marrow-derived cell groups, IGF-I supplementation significantly (P = 0.048) increased 
collagen type III mRNA expression. Monolayer FGF-2 expansion of bone marrow-derived 
cells had no effect (P = 0.523) on collagen type III expression.  
COMP mRNA expression 
          Overall, tendon-derived cell groups cultured with tendon matrix expressed 
significantly (P = 0.001) more COMP mRNA than bone marrow-derived cell groups (Figure 
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10). However, there was no significant effect of FGF-2 or IGF-I on COMP mRNA 
expression in either tendon- or bone marrow-derived cells. 
 
Collagen Synthesis  
          Although mean collagen synthesis of tendon-derived cell groups approached 
significance (P = 0.055), the synthesis rate was still less than that of bone marrow-derived 
cell groups (Figure 11). Monolayer expansion of tendon-derived cells with FGF-2 did not 
affect their subsequent collagen synthesis (P = 0.367). Further, IGF-I did not affect collagen 
synthesis by tendon-derived-cell groups (P = 0.055). There was no significant (P = 0.532) 
effect of FGF-2 expansion on collagen synthesis by bone marrow-derived cells when 
compared to the unsupplemented controls. However, collagen synthesis in the bone marrow-
derived cell grouos supplemented with IGF-I remained lower than collagen synthesis in the 
tendon-derived groups. 
 Collagen synthesis normalized to cell number 
         When values of collagen synthesis were normalized to cell number, no significant 
difference (P= 0.134) was seen in the per-cell collagen synthesis between tendon- and bone 
marrow-derived cell groups (Figure 12). Among the tendon-derived cell groups, monolayer 
expansion with FGF-2 had no significant effect (P = 0.342) on sequential per-cell collagen 
synthesis. However, supplementation of IGF-I significantly (P = 0.030) increased the per-cell 
collagen synthesis of tendon-derived cells in comparison to the supplemented control. In the 
bone marrow-derived cell groups, monolayer expansion of bone marrow-derived cells with 
FGF-2 had a favorable effect (P = 0.071) on sequential per-cell collagen synthesis. 
 54 
Supplementation of IGF-I had no significant (P = 0.671) effect on mean log collagen 
synthesis normalized to cell number in bone marrow-derived cell groups. 
 
GAG Synthesis  
          GAG synthesis was significantly (P = 0.0058) higher in the tendon-derived cell groups 
than the bone marrow-derived (Figure 13). Within the tendon-derived cell groups, 
monolayer expansion with FGF-2 significantly (P = 0.030) increased GAG synthesis. 
Further, IGF-I supplementation of tendon-derived cell:matrix cultures also increased GAG 
synthesis (P = 0.016). In the bone marrow-derived cell groups, monolayer expansion with 
FGF-2 had no effect (P = 0.305) on GAG synthesis. However, IGF-I significantly (P = 
0.022) increased GAG synthesis by bone marrow-derived cells, in comparison to 
unsupplemented cultures.  
GAG synthesis normalized to cell number 
         When GAG synthesis was normalized to cell number, overall, per-cell synthesis of 
tendon-derived cell groups approached significance (P = 0.066) in comparison to bone 
marrow-derived cell groups (Figure 14). However, there was no significant effect of 
supplementation with FGF-2 or IGF-I on per-cell GAG synthesis of tendon- or bone marrow-
















Table 1: Mean + SE values for cell number following monolayer expansion with or without 
FGF-2 supplementation in tendon- and bone marrow-derived cells. *Significant effect based 









Cell Type (+) FGF-2 (-) FGF-2 P- value 
Tendon-derived 
Cells 
15.34X106 + 2.597 X106 *‡ 9.14 X 106 + 1.03 X106 * 0.027 
Bone marrow-derived 
Cells 



















Figure 6. Bright field photomicrograph during monolayer expansion of tendon-derived cells 
with FGF-2 (A) and without FGF-2 (B), bone marrow-derived cells with FGF-2 (C) and 










Figure 7: Log mean + SE cell numbers present in each treatment group following expansion 
with and without FGF-2 and cultured for 7 days with and without IGF-I and pulverized 





























Figure 8: Mean ± SE values (log scale) for  collagen type I  mRNA expressionn normalized 
to EF1-α. The x- axis represents equine tendon- and bone marrow-derived cells expanded 
with and without FGF-2 and cultured for 7 days with and without IGF-I and pulverized 
acellular tendon matrix. § Significant effect of supplementation of IGF-I when compared to 














































Figure 9: Mean ± SE values (log scale) for collagen type III mRNA expression normalized 
to EF1-α. The x- axis represents equine tendon- and bone marrow-derived cells expanded 
with and without FGF-2 and cultured for 7 days with and without IGF-I and pulverized 
acellular tendon matrix. * Significant effect based on cell type. § Significant effect of 


















































Figure 10: Mean ± SE values (log scale) for collagen type III mRNA expression normalized 
to EF1-α. The x- axis represents equine tendon- and bone marrow-derived cells expanded 
with and without FGF-2 and cultured for 7 days with and without IGF-I and pulverized 










































Figure 11: Log mean + SE (DPM- disintegrations per minute) incorporation of [3H] proline 
into collagen of the matrix formed by the combination of cells and pulverized acellular 
tendon. Cells were expanded with and without FGF-2 and cultured for 7 days with and 
without IGF-I and pulverized acellular tendon matrix. § Significant effect of supplementation 





























Figure 12: Log mean DPM (disintegrations per minute) normalized to cell number + SE. 
Cells were expanded with and without FGF-2 and cultured for 7 days with and without IGF-I 

























Figure 13: Log mean + SE (CPM- counts per minute) incorporation of sulfur 35-labeled 
sodium sulfate into GAG of the matrix formed by the combination of cells and pulverized 
acellular tendon. Cells were expanded with and without FGF-2 and cultured for 7 days with 
and without IGF-I and pulverized acellular tendon matrix. * Significant effect based on cell 
type. ‡ Significant effect of monolayer expansion with FGF-2 in comparison to control. § 


































Figure 14: Log mean CPM (counts per minute) normalized to cell number + SE.  Cells were 
expanded with and without FGF-2 and cultured for 7 days with and without IGF-I and 


























         The objective of this study was to evaluate the effect of sequential growth factors, FGF-
2 and IGF-I on tendon-derived cells as a therapeutic option for cell-based therapies for the 
treatment of tendinitis. Bone marrow-derived cells were used as the gold standard for 
comparison. Overall, FGF-2 increased cell proliferation during monolayer expansion and 
IGF-I increased subsequent matrix synthesis in the tendon-derived cells. Tendon-derived 
cells were more proliferative in culture in vitro and required a shorter duration of time to 
generate clinically relevant numbers than bone marrow-derived cells. In addition, less inter-
animal variability was noted in statistics derived from tendon-derived cells when compared 
to bone marrow-derived cells. The results obtained in this study were derived from six young 
adult horses and the statistical power for significance ranged from 0.6 - 0.9. 
        This in vitro study suggests that tendon-derived cells can be obtained in sufficient 
numbers from an autogenous specimen for cell-based treatment of tendinitis in horses(Smith 
2008b); (Nixon et al. 2008, Schnabel et al. 2009). Recent studies have evaluated the presence 
of a stem cell population within a tendon extracellular matrix niche(Bi et al. 2007, de Mos et 
al. 2007a, Scutt, Rolf & Scutt 2008). Moreover, differentiation towards adipogenic, 
osteogeneic and chondrogenic pathways have been reported, confirming the multipotential 
capacity of the tendon stem cell populations in mice, rats, rabbits, horses, and humans(de 
Mos et al. 2007a, Scutt, Rolf & Scutt 2008). One study showed increased chondrogenic 
capacity of caprine tendon-derived cells in comparison to bone marrow-derived MSC 
controls, suggesting that tendon-derived progenitor cells are feasible for cell-based therapies 
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directed towards tissues other than tendon itself (Funakoshi, Spector 2010). In this study, 
tendon-derived cells, overall, had an increased expression of collagen type III mRNA when 
compared to bone marrow-derived cells. An increased expression of collagen type III can 
alter the collagen type I/type III ratio and eventually affect the quality of the resulting 
structure. Determinations of collagen type I and III protein production or consequent 
extracellular matrix organization were not performed in this study. These analyses will 
require an in vivo study, to clarify the clinical benefits of sequential FGF-2 and IGF-I 
administration for cell-based repair of tendon injuries. In addition, following monolayer 
expansion with FGF-2, both tendon- and bone marrow-derived cells were cultured in 
tenogenic medium with pulverized tendon and IGF-I. It is possible that this medium may 
have provided optimum conditions for matrix synthesis of tendon-derived cells versus bone 
marrow-derived cells.  
         In this study, FGF-2 significantly increased proliferation of tendon-derived cells during 
monolayer expansion; however, this effect was not significant in the bone marrow-derived 
cells. This contrast may be due to the considerable “between donor” variation in bone 
marrow aspirate responses. FGF-2 had minimal effects on cell viability and adherence of 
both tendon- and bone marrow-derived cells on acellular pulverized tendon. In addition, 
FGF-2 did not influence ECM gene expression or matrix synthesis in either cell type. There 
have been no previous reports describing the effect of FGF-2 expansion on subsequent 
activities of tendon-derived cells. In vitro studies, evaluating the effect of FGF-2 on bone 
marrow-derived MSCs have shown mitogenic effects and a protective effect on subsequent 
multilineage potential during proliferation in vitro (Stewart et al. 2009a, Tsutsumi et al. 
2001). Further, in vivo studies with intratendinous injections of FGF-2 in murine and canine 
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models demonstrated angiogenic stimulation in the early stages of tendon healing(Dahlgren, 
Mohammed & Nixon 2005, Chan et al. 2000)(Duffy et al. 1995, Chan et al. 1997). Based on 
this study, supplementation with FGF-2 should be considered to increase the proliferation 
rate of tendon-derived cells in vitro, without detrimental effects on subsequent matrix 
synthesis. 
Previously, an in vitro study described IGF-I enhanced tenocyte proliferation and 
matrix synthesis in equine tendon explants (Murphy 1997). In the current study, IGF-I 
increased collagen and proteoglycan synthesis in both tendon and bone marrow-derived cells, 
although this effect was only seen at a transcriptional level in the bone marrow derived cells. 
In addition, sequential administration of IGF-I to FGF-2 expanded tendon-derived cells 
significantly increased GAG synthesis when compared to tendon-derived cells without 
growth factor supplementation. These variables may alter per cell biosynthetic rates among 
the different treatment groups. These increases in matrix synthesis suggest that IGF-I 
supplementation is justified for tissue regeneration applications of both cell types, as 
supported by two recent in vivo studies that utilized the equine collagenase model of 
tendinitis (Dahlgren et al. 2002, Schnabel et al. 2009). Both these in vivo studies showed 
improvement in biomechanical properties which is a critical outcome for successful tendon 
repair. In this study, the improvement in gene expression and matrix synthesis was apparent 
in bone marrow-derived cells with IGF-I supplementation and is similar to other in vitro 
studies (Dahlgren, Nixon & Brower-Toland 2001, Murphy, Nixon 1997). However, the 
increases in gene expression and matrix synthesis by bone marrow-derived cells 
supplemented with IGF-I remained lower than the corresponding activities of tendon-derived 
cells supplemented with IGF-I.  
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In this in vitro study, acellular pulverized tendon was used to provide a three 
dimensional substrate for cell adherence with the goal of simulating the in vivo micro-
environment of a damaged tendon, in contrast to acellular tendon matrix explants which 
provide an intact, surface for attachment. Previous studies have shown tendon-derived cells 
had superior adherence to and viability on acellular tendon matrix explant than bone marrow-
derived cells (Stewart et al. 2009a).aa In contrast, the results from this study show no 
difference in viability between tendon- and bone marrow-derived cells in co-culture with  
pulverized matrix suspension. This suggests that the powdered tendon used in the current 
study have cell adhesion and survival properties that differ from acellular tendon matrix 
explants used previously. Further, acellular tendon explants may provide topographic cues 
for cell attachment due to the organized fiber pattern as present in vivo. Further work needs 
to be done to assess the differential effects of specific substrate characteristics on progenitor 
cell colonization and survival.    
Hind limb lateral digital extensor tenectomies were performed to obtain tendon-
derived cells and tendon matrix. In this technique, a 4 cm X 1 cm tendon specimen provided 
sufficient numbers of tendon-derived cells for potential clinical applications. This procedure 
is used clinically for the treatment of refractory stringhalt; however, the long-term safety and 
morbidity associated with lateral digital extensor tenectomies needs further evaluation. In 
addition, a recent study demonstrated metabolic and homeostatic differences between equine 
flexor and extensor tenocytes (Hosaka et al. 2010). Common digital extensor tenocytes were 
less proliferative and had reduced matrix synthetic capacity in vitro when compared to 
superficial and deep digital flexor tenocytes. It is possible that lateral digital extensor tendon-
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derived cells, although an expedient source of tendon-derived progenitors, are not 
biosynthetically ideal for the repair and/or regeneration of digital flexor tendon injuries. 
           In conclusion, the results of this study demonstrate that, in vitro, tendon-derived cells 
have increased matrix gene expression and matrix synthetic capacity when compared to bone 
marrow-derived cells. In general, growth factor supplementation had more pronounced 
effects on bone marrow-derived cells. However, tendon-derived cells proliferated more 
rapidly in monolayer culture than bone marrow-derived cells with FGF-2 supplementation. 
Also, GAG synthesis of tendon-derived cells was increased following FGF-2 supplemented 
monolayer expansion and IGF-I administration during cell:matrix suspension culture. 
Accepting these beneficial responses, these results were obtained in an in vitro model and 
require careful interpretation and in vivo assessment before translation into clinical therapies. 
Based on the results obtained from this study, further research in use of tendon-derived cells 
and growth factor enhancement of these cells for therapeutic applications in in vivo models of 
tendinitis is warranted.  
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Primers used for real-time PCR amplification of genes in this study of equine bone marrow- 
and tendon-derived cells  
 
Gene Sequence Amplicon 
(bp) 
Eq Col I (S) GAA AAC ATC CCA GCC AAG AA 
Eq Col I (A) GAT TGC CAG TCT CCT CAT CC 
231  
Eq Col III (S) AGG GGA CCT GGT TAC TGC TT 
Eq Col III (A) TCT CTG GGT TGG GAC AGT CT 
215  
Eq COMP (S) TCA TGT GGA AGC AGA TGG AG 
Eq COMP (A) TAG GAA CCA GCG GTA GGA TG 
223  
Eq EF1-α (S) CCC GGA CAC AGA GAC TTC AT 
Eq EF1-α (A) AGC ATG TTG TCA CCA TTC CA 
328  
      











a. Jamshidi bone marrow biopsy needle, Cardinal Health, Dublin, Ohio. 
b. DMEM, Mediumtech Inc, Herndon, Va. 
c. Gemini Bioproducts, Woodland, Calif. 
d. L-glutamine, 200 mM, Invitrogen, Carlsbad, Calif. 
e. Penicillin-streptomycin, BioWhittaker, Cambrex Bio Science, Walkersville, Md. 
f.          FGF-2, R & D systems, Minneapolis, MN. 
g. Collagenase type II, Worthington Biochemical Corp, Lakewood, NJ. 
h.         Freezer mill, SPEX Certi Prep, Matuchen, NJ. 
i.          IGF-I, R & D systems, Minneapolis, MN. 
j.          24 well ultra-low attachment plates, Fisher Scientific, Pittsburgh, PA.  
k.         Cell Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI. 
l.          Microplate reader, FLUOstar Optima, BMG Laboratories, Durham, NC. 
m.        Trizol, Invitrogen, Carlsbad, Calif. 
n.         Rneasy, Qiagen, Valencia, Calif. 
o.         Superscript II, Invitrogen, Carlsbad, Calif. 
p.          iQ SYBR Green Supermix, Bio-Rad Laboratories, Hercules, Calif. 
q.         ClustalW, www.ebi.ac.uk.  
r.          iCycler iQ real-time PCR detection system, Bio-Rad Laboratories, Hercules, 
            Calif. 
s.         [3H] proline, Sigma Chemical Co, St Louis, MO. 
t.          Hand-held or post-mounted homogenizer, Pro Scientific, Oxford, CT. 
u.         Collagenase, purified, Worthington Biochemical Corp, Lakewood, NJ. 
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v.         LS6500 Multi-purpose scintillation counter, Beckman Coulter Inc, Fullerton,     
            Calif. 
w.             35S- labeled sodium sulphate, MP Biochemicals, Irvine, Calif. 
x.         Papain, Sigma-Aldrich, St Louis, Mo. 
y.         Multiwell punch plates, PDVF plate, Millipore, Bedford, Mass. 
z.         R 2.9.1 statistical software, online at www.r-project.org. 
aa.       Durgam SS, Stewart AA, Pondenis H, et al. In vitro comparison of IGF-I  
            enhanced tendon- and bone marrow-derived progenitor cells cultured on tendon  
            matrix (abstr), in Proceedings. 43rd ACVS Symposium 2009. 
 
 
 
